🧬
Healthcare & Biotech 产品技术与架构落后 2010 - 2014

个性化肿瘤疗法的商业化困境 (Dendreon):第一个获批的癌症治疗性疫苗,为什么卖不动?

产品获批不等于商业模式成立——个性化疗法要先回答「怎么造、谁付钱」

个性化肿瘤疗法的商业化困境 (Dendreon):巅峰期生物技术公司的治疗性肿瘤疫苗,是首个获监管批准的前列腺癌免疫疗法,被视为个性化细胞治疗的里程碑,定价接近十万美元;终局是产品获批后因个性化制备成本高、支付方覆盖慢与产能投入过大,销售远低于预期,公司申请破产保护,产品与技术被出售给其他企业。

Official site
See the patterns

About this link:原地址会跳转到站内其他页面。

公开报道整理 待核查 Figures as of 2014 2 sources(1 primary) What do these mean?

How to read this bar

This bar states plainly what we know and what we have checked, so you can judge it yourself.

· Review status: “pending” means no editor has checked it against the sources yet; “checked” means key facts match the sources.

· Figures as of: the year the numbers are current to; later changes are out of scope.

· Sources: listed one by one at the bottom of the page. “Primary” means official filings, annual reports or regulator documents.

· Corrections: every change and its basis is published — nothing is edited silently.

Editorial policy → Editorial policy: the full inclusion rules, verification process, AI disclosure and correction promise.

No English translation for this case yet — showing the stored original.
Peak valuation

生物技术公司的治疗性肿瘤疫苗,是首个获监管批准的前列腺癌免疫疗法,被视为个性化细胞治疗的里程碑,定价接近十万美元

Final cost

产品获批后因个性化制备成本高、支付方覆盖慢与产能投入过大,销售远低于预期,公司申请破产保护,产品与技术被出售给其他企业

Attribution votes

4,983 votes cast

Community output

1 plans · 1 insights

Sponsored
把你亲历的失败写进来

投稿会先进入待审,通过后才进入公开目录和站点地图。

Root Causes Consensus Poll

Vote for the primary fatal error that caused this enterprise to collapse.

产品技术

个性化制备无法通过规模降本

每位患者需要独立生产流程,单位成本居高不下

1,639 votes (33%)
资本财务

产能建设先于需求验证

在销售路径未跑通时投入巨额固定资产,放大现金压力

1,377 votes (28%)
外部合规

支付方报销决策慢

高价疗法的覆盖流程复杂,实际可及患者少于预期

1,115 votes (22%)
战略

单一产品缺少缓冲

公司只有一款产品,任何商业节奏偏差都直接冲击生存

852 votes (17%)

Sources

2 sources · 1 primary

These are the references used to compile this case; the numbers match the [1][2] marks in the timeline. Primary sources come first, and archive links are kept where possible.

1 of these are overseas sites (Wikipedia, the Internet Archive, etc.) that may be unreachable from mainland China, so domestic sources (Baidu Baike, mainstream financial media, exchange filings) have been added wherever possible.

  1. [1]
    官方网站(Wikidata 登记) Primary 官方资料
    dendreon.com Accessed 2026-10-04
  2. [2]
    维基百科:Dendreon 其他 Overseas site
    Wikipedia Accessed 2026-10-04